Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT03498716 · Hoffmann-La Roche · PHASE3 · terminated · last registry update 2024-08-21 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT02883062)
- 2023-12-12Results posted on the registry: Dana-Farber Cancer Institute, Palbociclib + Fulvestrant (NCT03147287)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
- 2023-10-27Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06103864)
- 2023-09-28Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT06058377)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision